XPH:NYE-SPDR® S&P Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 43.41

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.09M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.57 (+0.41%)

USD 36.67B
FHLC Fidelity® MSCI Health Care In..

+0.15 (+0.23%)

USD 2.62B
FXH First Trust Health Care AlphaD..

+0.21 (+0.20%)

USD 1.09B
XHE SPDR® S&P Health Care Equipme..

+0.55 (+0.62%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.04 (+0.18%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-0.04 (-0.12%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

+0.28 (+0.31%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+0.11 (+0.37%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+0.07 (+0.11%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.01 (+0.03%)

USD 0.01B

ETFs Containing XPH

INAV 10.31 % 0.00 %

N/A

N/A
MSSS Northern Lights Fund Trus.. 9.93 % 0.00 %

+0.25 (+0.90%)

USD 0.11B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.30% 76% C+ 51% F
Dividend Return 1.63% 100% F 28% F
Total Return 5.93% 81% B- 44% F
Trailing 12 Months  
Capital Gain 4.96% 76% C+ 53% F
Dividend Return 1.64% 100% F 28% F
Total Return 6.60% 86% B+ 47% F
Trailing 5 Years  
Capital Gain -6.32% 19% F 42% F
Dividend Return 5.54% 68% D+ 15% F
Total Return -0.78% 24% F 27% F
Average Annual (5 Year Horizon)  
Capital Gain -1.46% 14% F 25% F
Dividend Return -0.74% 19% F 17% F
Total Return 0.72% 68% D+ 19% F
Risk Return Profile  
Volatility (Standard Deviation) 16.05% 67% D+ 64% D
Risk Adjusted Return -4.60% 14% F 18% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.